Notice of Intent to Publish a Funding Opportunity Announcement for Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)

0
242

Opportunity ID: 310199
Opportunity Number: NOT-NS-19-009
Opportunity Title: Notice of Intent to Publish a Funding Opportunity Announcement for Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s):
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Nov 05, 2018
Last Updated Date: Nov 05, 2018
Estimated Synopsis Post Date: Nov 15, 2018
Fiscal Year: 2019
Award Ceiling:
Award Floor:
Estimated Total Program Funding:
Expected Number of Awards:
Description: The National Institute of Neurological Disorders and Stroke (NINDS) with other NIH Institutes and Centers participating in the HEAL (Helping to End Addiction Long-term) Initiative, intends to publish a Funding Opportunity Announcement (FOA) to support the development of therapeutic, diagnostic, and rehabilitative technologies for pain. The focus of this FOA will be to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program will be to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. The FOA will facilitate the translation of new devices by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology optimization, regulatory activities to enable IDE/IRB approvals, and a subsequent clinical study. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in 2018 with an expected application due date in 2018. This FOA will utilize the UG3/UH3 activity code. Details of the planned FOA are provided below.
Version: 1





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement for Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)